Key Insights

Highlights

Treatment Research

5 treatments under study, led by Not Applicable Noninterventional Study

Research Leaders

6 sponsors active, led by Action Medical Research

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 4 trials

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Phase 2 (1)
Phase 3 (1)

Trial Status

Unknown2
Recruiting2

Clinical Trials (4)

Showing 4 of 4 trials
NCT06867991Phase 3RecruitingPrimary

Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis

NCT06510283Phase 2RecruitingPrimary

Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 Encephalitis

NCT05280600UnknownPrimary

Developing Advanced Neuroimaging for Clinical Evaluation of Autoimmune Encephalitis

NCT02443350UnknownPrimary

Multicenter and Prospective Clinical Registry Study of Anti-N-methyl-D-aspartate Receptor Encephalitis in Beijing Area

Showing all 4 trials

Research Network

Common Treatments

  • Not Applicable Noninterventional Study1
  • Taitacept1
  • Ofatumumab Combined With Daratumumab1
  • Repeated Intravenous Immunoglobulinplasma Exchange Therapy1
  • Ofatumumab1

Active Sponsors

  • Action Medical Research1
  • King's College London1
  • Guy's and St Thomas' NHS Foundation Trust1
  • Jia Wei Wang,MD1
  • The First People's Hospital of Changzhou1

Top Investigators

Related Conditions

  • Autoimmune Encephalitis1

Activity Timeline